Trials / Completed
CompletedNCT00410592
Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD
A Randomized, Open-Label, Comparative 3-Way Crossover Study of 24-Hour Intragastric pH Profile of Once Daily Oral Administration of Esomeprazole 40 mg, Lansoprazole 30 mg, and Pantoprazole 40 mg at Steady State in Hispanic Patients With Symptomatic GERD
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 69 Years
- Healthy volunteers
- Not accepted
Summary
This study will be conducted in order to determine safety and efficacy esomeprazole, lansoprazole and pantoprazole control stomach acid by measuring the stomach acid in men and women of Hispanic origin who have GERD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Esomeprazole 40mg | |
| DRUG | Pantoprazole 40mg | |
| DRUG | Lansoprazole 30mg |
Timeline
- Start date
- 2006-10-01
- Completion
- 2007-05-01
- First posted
- 2006-12-13
- Last updated
- 2009-03-11
Locations
8 sites across 2 countries: United States, Puerto Rico
Source: ClinicalTrials.gov record NCT00410592. Inclusion in this directory is not an endorsement.